一台设备，仅需 20 分钟，就能准确地测出你的饮酒水平，并帮你评定从"一星酒渣"到"五星 酒神" 5 个不同的等级，更能个性化地指导如何健康饮酒！ 文｜《好博会》报道组 刘丽丽 这样的设备来自华大智造研发的"饮鉴"，如今它已经成为社交利器。那么，这个被称为是首 个基因科技"现场级"体验产品，到底是怎样的神奇仪器？ 云南腾冲和顺古镇景区提供"饮鉴"测试服务 谦宿公司旗下饭店的测试仪器 20分钟 知道你是酒渣还是酒神 据华大智造研发总监耿春雨介绍，"饮鉴"是首个现场 20 分钟立等可取的基因检测工具，能 够通过"微测序"精准对个人酒精代谢的能力进行基因层面的解读，把人群区分为"一星酒 渣"到"五星酒神" 5 个不同的等级，个性化的指导如何能够以更加健康的饮酒方式上酒桌。 耿春雨表示，华大一直在思考能不能找到突破口让测序技术被更多人了解，而酒精代谢是一 个很好的选择。他介绍了这款产品的原理：酒的关键成分是"乙醇"，乙醇进入体内经过乙醇 脱氢酶代谢为乙醛，然后乙醛又被乙醛脱氢酶代谢为乙酸，进而再转化为无害物质积存体内 或者排除。而乙醇脱氢酶和乙醛脱氢酶根据基因型的不同在每个人身体内表现为不同强弱的 代谢能力。 可重复 ...

英国研究人员在新一期美国《神经肿瘤学杂志》上发表论文介绍，他们新开发出一种超快速脑肿瘤基因 诊断方法，可以将脑肿瘤的诊断时间从此前的6至8周缩短至2小时。（新华社） ...

Summary of Key Points Core Viewpoint - The announcement details a significant change in shareholding for Chengdu Berry Genomics Technology Co., Ltd. (referred to as "the Company") due to forced execution of shares by the controlling shareholder Gao Yang and his associate Hou Ying, resulting in a reduction of their holdings without affecting the company's control or operational stability [1][2]. Shareholding Changes - Gao Yang's shares decreased by 5,580,549 shares, representing a 1.58% reduction in total shareholding [1]. - Hou Ying's shares decreased by 1,135,661 shares, accounting for 0.32% of total shareholding [1]. - The total reduction in shareholding for both Gao Yang and Hou Ying amounts to 6,716,210 shares, which is 1.90% of the total share capital [1]. Execution Details - The forced execution of shares occurred due to a stock pledge default, with the shares being sold through centralized bidding by Guoxin Securities from August 1, 2024, to October 31, 2024, and again on May 20, 2025 [1]. - The execution process did not lead to a change in the company's control, nor did it have a significant adverse impact on the company's production, financial status, or governance structure [2].

2025.05. 21 微信编辑 | 苏小 据澎湃新闻报道，5月20日，针对张核子公司前员工执行款3个月未到账一事，深圳市南山区法院回应称，该执行案张核子公司申请了 执行异议，法院希望双方调解结案，并两次延长了审限。目前，法院支持了张核子的执行异议，并将21.30万元已划扣到法院账上的执 行款返还给了张核子公司。 推荐阅读 中方正告：必将付出沉重代价！ 爱企查App显示，张核子名下关联16家企业，涉及基因、生物、通信等领域，其中仅5家为开业状态，包括深圳市核子基因科技有限公 司、深圳市核子生物科技有限公司、长沙核子华曦医学检验有限公司等。在上述为开业状态的企业中，张核子担任法定代表人、执行 董事、总经理等职务。 值得一提的是，风险信息显示，张核子旗下的深圳市核子基因科技有限公司曾因"劳动合同纠纷"被多次起诉。 本文字数：365，阅读时长大约0.5分钟 | 童金业 查老板 | 查关系 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 张核子 | | 搜索 ੋਲ | | 应用 ▼ 刘 新客4.9元 | APP | 11 11 | | 关联企业 96 ...

位于青岛高新区的山东极智生物科技有限公司实验室内，技术人员用超薄切片机处理一片植物根尖样 本，肉眼难辨的根尖组织截面图在显示屏上呈现层层叠叠的彩色网格，像一幅抽象派油画。 "这是空间条形码芯片，每一个点对应组织的一个坐标点，用来检测基因在染色体上的空间位置和信 息。切片后，RNA（核糖核酸）会带着'地址标签'进入测序仪，还原出基因表达在空间上的'热力 图'。"极智生物技术员潘宏伟告诉记者，这种时空转录组切片技术处于行业领先水平。 瞄准行业难题，极智生物持续开展技术攻关。"以时空转录组切片技术为例，样本处理环节困难重 重。"潘宏伟说，植物组织的结构复杂，不同细胞类型和组织层次紧密相连，在切片过程中极易造成组 织变形、RNA降解等问题，严重影响后续基因表达信息的准确获取。为此，技术团队进行了上百次实 验，尝试多种切片方法和样本固定液配方，最终找到一种能够最大程度保持组织形态完整、减少RNA 降解的处理方案。 作为基因检测领域的高新技术企业，极智生物主要从事数字育种CRO（合同研发组织）服务及高产优 质+耐逆+抗病小麦新品种创制研发。"公司基于自主搭建的功能基因位点数据库、先进的基因检测技术 平台、AI驱动的精准育 ...

Core Viewpoint - The announcement highlights that a significant shareholder of Berry Genomics, Gao Yang, is subject to judicial enforcement regarding the forced liquidation of a portion of his shares due to a breach of contract with Guoxin Securities [1][2]. Group 1: Shareholder and Legal Actions - Gao Yang, the controlling shareholder of Berry Genomics, holds 31,988,723 shares, accounting for 9.05% of the total share capital [1]. - The Chengdu Financial Court has ordered the forced liquidation of 3,535,214 shares held by Gao Yang due to a breach of a stock pledge repurchase agreement with Guoxin Securities [1][2]. - The enforcement action is based on a legally effective arbitration ruling from the Shenzhen International Arbitration Court [1]. Group 2: Financial Performance - Berry Genomics reported net profits attributable to shareholders of -117 million yuan in 2021, -249 million yuan in 2022, -427 million yuan in 2023, and -192 million yuan in 2024 [3]. - The company's operating revenue for 2024 is 1,078 million yuan, a decrease of 6.36% from 2023, which had revenue of 1,151 million yuan [4]. - The net profit attributable to shareholders for 2024 improved by 54.96% compared to 2023, indicating a reduction in losses [4].

海外基因检测行业点评 GRAIL 一步一印一前进，AI+医疗开启应用新篇章 2025 年 05 月 15 日 ➢ 事件：美国癌症早筛龙头 Grail 于美国时间 2025 年 5 月 13 日发布 2025 年 Q1 业绩：2025Q1，Grail 收入达 3,180 万美元，同比增长 19%。 ➢ Galleri 产品销售符合预期，重复测试比例超 20%。分产品来看，1）Galleri 筛查收入 2,910 万美元，同比增长 24%，美国地区 Galleri 收入达 2,870 万美 元，同比增长 22%，符合年初设定的全年 20% - 30%的增长指引，销售量为 超 37,000 份，重复测试量随时间增加，目前超 20%的 Galleri 测试为重复测 试；2）开发服务收入为 270 万美元，开发服务收入来自为生物制药和临床客 户提供的服务。 ➢ 商业化合作进展顺利，在手现金有望将公司正常运营持续至 2028 年。公 司于 2025 年年初达成同 QUEST 的合作以及进入了美国军方 TRICARE 商保 的覆盖，目前通过 QUEST 平台下单的情况有所改善，TRICARE 方面正在与各 承包商进行签约流 ...

Group 1 - Turkish clinical genetic testing laboratory Genoks has announced a partnership with BGI Genomics to enhance its clinical testing capabilities in the local market [1] - The collaboration involves the introduction of BGI's sequencing platform and supporting products [1] - This partnership aims to empower local public health initiatives and advance genomic research in Turkey [1]

（行政处罚信息。上海市市场监管局官网/截图） 相关通知称，近期公司面临增资，主要经营账户却被个别股东恶意冻结，业务收入断崖式下滑，导致公 司日常运营面临巨大挑战。基于此，公司经过慎重评估，不得不作出停工停产的决定。停工停产涉及人 员为至本医疗集团及分子公司、外包公司及全体员工。 至本医学允许王某某将前述费用，以餐饮费、打车费名义进行报销。经审计，通过上述方式，至本医学 最终实际获得基因检测业务订单309笔，涉案销售金额为477.62万元，违法所得共计229.2万元。 上海市普陀区市场监管局认为，当事人至本医学上述行为，违反了《中华人民共和国反不正当竞争法》 第七条第一款第（三）项之规定，构成不正当竞争行为。 2025年1月13日，上海市普陀区市场监管局对至本医学没收违法所得229.2万元，罚款100万元，合计罚 没金额为329.2万元。 上海市普陀区市场监管局在科普文章中称，涉案企业企图通过虚假报销、隐匿资金流向等手段掩盖对医 生行贿的违法事实。案件始于患者举报——某医院医生与上海某医学检验所员工王某某的异常往来。 执法部门突破重重阻碍，通过逐一梳理涉案订单资金流向、核实销售人员的实际工作内容、劳务关系 等， ...

Group 1 - The core viewpoint of the news highlights the recent performance and market position of Berry Genomics, noting a significant stock price increase and a low market-to-book ratio [1] - On May 13, Berry Genomics closed at 13.96 yuan, up 10.01%, with a market capitalization of 4.935 billion yuan and a price-to-book ratio of 2.96, marking a new low in 31 days [1] - The company experienced a net inflow of 137.79 million yuan in main funds on May 13, with a total inflow of 102.66 million yuan over the past five days, indicating a positive trend in capital flow [1] Group 2 - Berry Genomics specializes in gene testing services based on high-throughput sequencing technology, offering related equipment and reagent sales [1] - The company provides comprehensive solutions through "products + services" to hospitals and third-party medical laboratories, establishing a leadership position in the genetics field [1] - The latest financial report for Q1 2025 shows the company achieved revenue of 218 million yuan, a year-on-year decrease of 22.08%, with a net loss of approximately 6.46 million yuan, reflecting a year-on-year decline of 178.47% and a gross profit margin of 49.48% [1] Group 3 - In comparison to industry averages, Berry Genomics has a TTM PE ratio of -23.83 and a static PE ratio of -25.65, with a market capitalization of 4.935 billion yuan [2] - The industry average PE ratios are significantly higher, with the average TTM PE at 50.06 and the static PE at 45.92, indicating that Berry Genomics is underperforming relative to its peers [2] - The industry median market capitalization is 4.795 billion yuan, suggesting that Berry Genomics is positioned within a competitive landscape [2]